PE20020578A1 - Una composicion de antibiotico topico para el tratamiento de infecciones oculares - Google Patents

Una composicion de antibiotico topico para el tratamiento de infecciones oculares

Info

Publication number
PE20020578A1
PE20020578A1 PE2001000995A PE2001000995A PE20020578A1 PE 20020578 A1 PE20020578 A1 PE 20020578A1 PE 2001000995 A PE2001000995 A PE 2001000995A PE 2001000995 A PE2001000995 A PE 2001000995A PE 20020578 A1 PE20020578 A1 PE 20020578A1
Authority
PE
Peru
Prior art keywords
amino
composition
oxazolidinone
oxazolidinyl
oxo
Prior art date
Application number
PE2001000995A
Other languages
English (en)
Inventor
Rebanta Bandyopadhyay
Pamela J Secreast
Leslie C Hawley
Vincent E Mccurdy
Praveen Tyle
Paramita Bandyopadhyay
Satish Singh
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of PE20020578A1 publication Critical patent/PE20020578A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION OFTALMOLOGICA QUE COMPRENDE: a)DE 0,1mg/ml A 200mg/ml DE OXAZOLIDINONA DE FORMULA I, DONDE R1 ES H, ALQUILO C1-C8, AMINO, DIALQUIL C1-C8-AMINO, ALCOXILO C1-C8; R2 Y R3 SON H, F, Cl; R4 ES H, CH3; R5 ES H, CH3, CN, CO2R1, (CH2)mR6; R6 ES H, OH, OR1, OCOR1, NHCOR1, AMINO, DIALQUIL C1-C8-AMINO; m ES 1-2; X ES O, S, SO, SO2, SNR7, SONR7; R7 ES H, ALQUILO C1-C4, p-TOLUENSULFONILO; DE PREFERENCIA LINEZOLID, EPEREZOLID, N[[(5S)-3-[4-(1,1-DIOXIDO-4-TIOMORFOLINIL)-3,5-DIFLUOROFENIL]-2-OXO-5-OXAZOLIDINIL]METIL]ACETAMIDA; CLORHIDRATO DE (S)-N-[[3-[5-(4-PIRIDIL)PIRID-2-IL]-2-OXO-5-OXAZOLIDINIL]METIL]ACETAMIDA; ENTRE OTROS; b)EXCIPIENTES QUE AUMENTAN LA VISCOSIDAD COMO CARBOXIMETILCELULOSA DE SODIO; REDUCEN LA VELOCIDAD DE ELIMINACION A TRAVES DE LAS LAGRIMAS; SIENDO EL TIEMPO DE ALOJAMIENTO DE 2 A 24 HORAS; SIENDO LA CONCENTRACION DEL PRINCIPIO ACTIVO EN EL LIQUIDO LAGRIMAL SUPERIOR A MCI90 POR 2 HORAS DESPUES DE LA APLICACION; SIENDO UNA COMPOSICION PREFERIDA DE 0,4mg/ml A 80mg/ml DE OXAZOLIDINONA; DE 0,1% A 2,5% DE UN AGENTE DE GELIFICACION COMO CARRAGENINA CON DISACARIDOS CON NO MAS DE DOS GRUPOS SULFATOS; CONSERVANTE COMO IMIDAZOLIDINIL-UREA, METILPARABENO, ENTRE OTROS; ADEMAS LA COMPOSICION COMPRENDE OTROS ANTIBACTERIANOS COMO AMIKACINA, AZITROMICINA, CEFIXIMA, CEFOPERAZONA, CLINDAMICINA, ENTRE OTROS; U OTROS FARMACOS COMO ACEBUTOLOL, ACECLIDINA, ACIDO ACETILSALICILICO, ALPRENOLOLAMILORIDE, ACIDO AMINOCAPROICO
PE2001000995A 2000-10-10 2001-10-09 Una composicion de antibiotico topico para el tratamiento de infecciones oculares PE20020578A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23913600P 2000-10-10 2000-10-10
US28534001P 2001-04-20 2001-04-20

Publications (1)

Publication Number Publication Date
PE20020578A1 true PE20020578A1 (es) 2002-08-14

Family

ID=26932302

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000995A PE20020578A1 (es) 2000-10-10 2001-10-09 Una composicion de antibiotico topico para el tratamiento de infecciones oculares

Country Status (9)

Country Link
US (1) US6551584B2 (es)
EP (1) EP1324748A1 (es)
JP (1) JP2004510809A (es)
AR (1) AR031135A1 (es)
AU (1) AU2001296753A1 (es)
CA (1) CA2424444A1 (es)
MX (1) MXPA03003168A (es)
PE (1) PE20020578A1 (es)
WO (1) WO2002030395A1 (es)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
US6540990B2 (en) 2000-09-22 2003-04-01 Gerard M. Nolan Physiological method of improving vision
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
PE20021017A1 (es) * 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
WO2002085865A1 (en) * 2001-04-20 2002-10-31 Pharmacia & Upjohn Company A method for the preparation of oxazolidinones
CA2445606A1 (en) * 2001-05-11 2002-11-21 Pacific Pharmaceuticals Limited Taste masking pharmaceutical composition
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
US20030069235A1 (en) * 2001-09-14 2003-04-10 J. Greg Slatter Treatment for ocular infections
MXPA01013257A (es) * 2001-12-18 2003-06-25 Arturo Jimenez Bayardo Suspension oftalmica de rofecoxib para el tratamiento de la inflamacion y el dolor ocular.
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US7176005B2 (en) * 2002-02-04 2007-02-13 The Regents Of The University Of California Modulation of sulfate permease for photosynthetic hydrogen production
KR100445437B1 (ko) * 2002-02-08 2004-08-21 한국과학기술연구원 네오마이신-옥사졸리디논 헤테로 이합체, 그의 제조방법및 그의 용도
MXPA04008171A (es) * 2002-02-22 2004-11-26 Pharmacia Corp Formulacion oftalmica con sistema de goma.
WO2003072141A1 (en) * 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
MXPA05005587A (es) * 2002-11-27 2005-07-27 Pharmacia Corp Composicion liquida concentrada de valdecoxib.
US20040137079A1 (en) * 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US20040202687A1 (en) * 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
CA2522043A1 (en) * 2003-04-25 2004-11-11 Gerard M. Nolan Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage
US8313776B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US8460710B2 (en) 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
KR101052705B1 (ko) * 2003-11-14 2011-08-01 센주 세이야꾸 가부시키가이샤 아미노글리코시드계 항생물질 및 브롬페낙을 함유하는수용액 제제
DE602004018990D1 (de) * 2004-05-26 2009-02-26 Bayardo Arturo Jimenez Verfahren zur herstellung einer latanoprost-augenlösung und so hergestellte lösung
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
FR2876581B1 (fr) 2004-10-20 2007-05-18 Interpharm Dev Composition bioadhesive a liberation programmee
US20060106117A1 (en) * 2004-11-12 2006-05-18 Kimberly-Clark Worldwide, Inc. Compound and method for prevention and/or treatment of vaginal infections
US7619008B2 (en) * 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
WO2006059221A2 (en) * 2004-12-03 2006-06-08 Pharmacia & Upjohn Company Llc Topical hydro-alcoholic formulations of oxazolidinone antibacterial agents
WO2006079896A2 (en) * 2005-01-27 2006-08-03 Pharmacia & Upjohn Company Llc Stable polyol formulations of oxazolidinone antibacterial agents
US20060223765A1 (en) * 2005-03-30 2006-10-05 Kimberly-Clark Worldwide, Inc. Method for inhibiting and/or treating vaginal infection
TWI393567B (zh) * 2005-03-31 2013-04-21 Bausch & Lomb 治療乾眼之組合物及相關之製造方法及使用方法
PL1906916T3 (pl) * 2005-05-10 2009-02-27 Alcon Inc Zawiesina do oczu obejmująca lek okulistyczny, poloksaminę i glikolowy środek regulujący toniczność, zastosowanie wymienionej kompozycji do wytwarzania leku do leczenia zaburzeń wzroku
PL1885336T3 (pl) * 2005-05-10 2009-08-31 Alcon Inc Kompozycja w postaci zawiesiny zawierająca substancję aktywną, poloksamerowy lub meroksapolowy surfaktant i glikol oraz zastosowanie kompozycji do wytwarzania leku do leczenia chorób oczu
JP2008544979A (ja) 2005-06-29 2008-12-11 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌剤としてのホモモルホリンオキサゾリジノン
US7786176B2 (en) 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
JP5200365B2 (ja) * 2005-11-30 2013-06-05 大正製薬株式会社 粘膜適用液剤
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
EP1962803A1 (en) * 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US20080020064A1 (en) * 2006-07-21 2008-01-24 Advanced Vision Research Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
DK2049112T3 (da) * 2006-08-07 2012-04-23 Bausch & Lomb Behandling af infektioner og følgesygdomme deraf med kombinerede, dissocierede glucocorticoid-receptor-agonister og anti-infektionsmidler
WO2008057364A1 (en) * 2006-11-02 2008-05-15 Riolan Technologies, Inc. Method for treating blepharitis
UY31058A1 (es) * 2007-05-01 2008-10-31 Alcon Res Ltd Formulaciones de aminoacido n-halogenado con compuestos antiinflamatorios
TW200904485A (en) * 2007-05-18 2009-02-01 Alcon Res Ltd Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions
CN101259135B (zh) * 2008-04-16 2010-06-09 韩耀云 一种兽用止泻药物组合物及其配置方法
RU2469726C2 (ru) 2008-05-14 2012-12-20 Отономи, Инк. Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней
US8349806B2 (en) * 2008-07-10 2013-01-08 Inspire Pharmaceuticals, Inc. Method of treating blepharitis
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
MX2011005586A (es) * 2008-12-22 2011-06-20 Alcon Res Ltd Composiciones de soluciones oculares topicas para suministrar concentraciones efectivas de agente activo al segmento posterior del ojo.
AU2010207010A1 (en) * 2009-01-20 2011-08-11 Advanced Vision Research, Inc. Methods and compositions for the treatment and prevention of infections
US20100190734A1 (en) * 2009-01-23 2010-07-29 Romulus Kimbro Brazzell Method of treating dry eye disease with azithromycin
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
EP2437743A4 (en) * 2009-06-05 2012-11-28 Aciex Therapeutics Inc OPHTHALMIC FORMULATIONS OF FLUTICASONE AND METHODS OF USE
US8679511B2 (en) * 2009-10-01 2014-03-25 Duquesne University of the Holy Spririt In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
US20120277199A1 (en) * 2009-10-21 2012-11-01 Otonomy, Inc. Modulation of Gel Temperature of Poloxamer-Containing Formulations
SI2965749T1 (sl) 2009-12-03 2018-09-28 Novartis Ag Suspenzije nanodelcev, ki vsebujejo karboksivinilni polimer
US20120190653A1 (en) * 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
WO2012104874A2 (en) * 2011-02-02 2012-08-09 Mylan Laboratories Limited. Aqueous concentrated formulation of linezolid
AU2012245538B2 (en) * 2011-04-22 2017-06-15 Alcon Research, Ltd. Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents
TWI544922B (zh) * 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
EP2726489A1 (en) 2011-06-30 2014-05-07 DSM IP Assets B.V. Silicone-containing monomer
US20150238473A1 (en) 2012-09-27 2015-08-27 University Of Rochester Methods and compositions for treating infection
GR1008143B (el) * 2013-03-11 2014-03-14 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον ενα οξαζολιδινονικο αντιβακτηριακο παραγοντα και μεθοδος για την παρασκευη αυτου
US9889145B2 (en) 2013-04-23 2018-02-13 The Administrators Of The Tulane Educational Fund Methods to treat infections
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac
MX2016002408A (es) 2013-08-27 2016-10-28 Otonomy Inc Metodos para el tratamiento de trastornos oticos pediatricos.
JP6363833B2 (ja) * 2013-11-22 2018-07-25 ナノシータ株式会社 薄膜状高分子構造体
SI2898888T1 (sl) * 2014-01-22 2019-06-28 Visufarma B.V. Sestavek, ki obsega iota-karagenan, proti virusnemu konjunktivitisu
US9241971B1 (en) 2014-07-18 2016-01-26 Kurobe, Llc Topical vancomycin formulation and methods of use
US10058542B1 (en) * 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
WO2017066964A1 (en) 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
US20190209466A1 (en) * 2016-09-06 2019-07-11 Dexcel Pharma Technologies Ltd. Ophthalmic compositions
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
CA3062420A1 (en) * 2017-05-05 2018-11-08 Gregory J. PAMEL Composition containing chlorine dioxide and methods for using same
EP3709970A1 (en) 2017-11-16 2020-09-23 Persica Pharmaceuticals Ltd. Linezolid formulations
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
WO2021184339A1 (en) * 2020-03-20 2021-09-23 Merck Sharp & Dohme Corp. Oxazolidinone compound and methods of use thereof as an antibacterial agent
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
US20240000801A1 (en) * 2022-05-25 2024-01-04 Axar Laboratories, Inc. Topical otic, ophthalmic, and nasal corticosteroid formulations

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
SE352811B (es) 1971-06-04 1973-01-15 Pharmacia Ab
US3960150A (en) 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
SE375007B (es) 1972-11-30 1975-04-07 Pharmacia Ab
US3914402A (en) 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
US3963025A (en) 1974-09-16 1976-06-15 Alza Corporation Ocular drug delivery device
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4057619A (en) 1975-06-30 1977-11-08 Alza Corporation Ocular therapeutic system with selected membranes for administering ophthalmic drug
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4303637A (en) 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4559343A (en) 1982-09-07 1985-12-17 Alcon Laboratories, Inc. Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents
US4478818A (en) 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5164510A (en) 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
FR2653021A1 (fr) 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
US5231188A (en) 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5275820A (en) 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5190927A (en) 1991-07-09 1993-03-02 Merck & Co., Inc. High-glyceryl, low-acetyl gellan gum for non-brittle gels
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
DK0610265T3 (da) 1991-11-01 1997-06-09 Upjohn Co Substituerede aryl- og heteroarylphenyloxazolidioner, som kan anvendes som antibakterielle midler
NO304832B1 (no) 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JPH09500901A (ja) 1993-07-28 1997-01-28 インサイト・ビジョン・インコーポレイテッド 薬剤供給用懸濁液
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
DE69419523T2 (de) 1993-11-22 1999-11-25 Upjohn Co Substituierte hydroxyacetyl piperazine phenyl oxazolidinonsäureester
DE4425613A1 (de) 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE4425612A1 (de) 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
IT1273742B (it) 1994-08-01 1997-07-09 Lifegroup Spa Composizioni ad elevata bioadesivita' e mucoadesivita' utili per il trattamento di epitali e mucose
PL184709B1 (pl) 1994-08-30 2002-12-31 Scherer Ltd R P Opakowanie dawek cieczy zwłaszcza płynu leczniczego
ZA962214B (en) 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
GB9601666D0 (en) 1996-01-27 1996-03-27 Zeneca Ltd Chemical compounds
US5837870A (en) 1996-04-11 1998-11-17 Pharmacia & Upjohn Company Process to prepare oxazolidinones
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP4439596B2 (ja) 1997-06-13 2010-03-24 サイデクス ファーマシューティカルズ、 インク． 長期の貯蔵寿命を有する、極性薬物又は極性プロドラッグを含有する医薬組成物、及びその製造方法
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
US6075130A (en) 1997-11-12 2000-06-13 Battelle Memorial Institute Ion binding compounds, radionuclide complexes, methods of making radionuclide complexes, methods of extracting radionuclides, and methods of delivering radionuclides to target locations
WO1999043333A1 (en) 1998-02-27 1999-09-02 The Althexis Company Therapeutic and prophylactic uses of negatively charged substituted disaccharides
EP1096934B1 (en) 1998-07-14 2005-09-21 Pharmacia & Upjohn Company LLC Oxazolidinones to treat eye infections
AR020660A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
EP1212058B1 (en) * 1999-09-13 2006-08-23 Insite Vision Incorporated Topical treatment for prevention of ocular infections
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)

Also Published As

Publication number Publication date
EP1324748A1 (en) 2003-07-09
MXPA03003168A (es) 2003-07-14
US6551584B2 (en) 2003-04-22
AU2001296753A1 (en) 2002-04-22
WO2002030395A1 (en) 2002-04-18
JP2004510809A (ja) 2004-04-08
US20020107238A1 (en) 2002-08-08
AR031135A1 (es) 2003-09-10
CA2424444A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
PE20020578A1 (es) Una composicion de antibiotico topico para el tratamiento de infecciones oculares
ES2278799T3 (es) Sistema de gelificacion reversible para distribucion de medicamentos oculares.
ES2374444T3 (es) Composiciones farmacéuticas acuosas autoconservadas.
ES2803648T3 (es) Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
JP4856392B2 (ja) 防腐剤及びこれを含有する水性組成物
JP2021035984A (ja) ポビドンヨード、眼科用組成物のための新規代替保存剤
JP2005521691A (ja) シクロデキストリン化合物及び塩化セチルピリジニウムを含有する眼科用抗菌性薬物製剤
PE20020044A1 (es) Tiazina oxazolidinona
JP2011006448A (ja) 第四級化アンモニウムシクロデキストリン化合物
JP2021157197A (ja) シリコーンハイドロゲルコンタクトレンズ用眼科組成物
ES2835398T3 (es) Métodos y composiciones para la administración oftálmica diaria de fentolamina para mejorar el rendimiento visual
TWI832920B (zh) 抑制軟性隱形眼鏡變質之眼科用組成物
MX2014013444A (es) Composiciones oftalmicas con retención y proteccion de desecación mejoradas.
KR20190065237A (ko) 안과용 제품 및 점도 저하 억제 방법
JP4863589B2 (ja) 水性組成物
JP2013529636A (ja) 胞子形成微生物の減少を増強するための組成物及び方法
JP4751482B2 (ja) コンタクトレンズ用液剤
US9138481B2 (en) Cellulosic gel composition with improved viscosity stability
PE20020300A1 (es) Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
JP5584336B2 (ja) 防腐剤及びこれを含有する水性組成物
DE60030300D1 (de) Topische behandlung zur vorbeugung von augeninfektionen
PE20020236A1 (es) Composicion que comprende una oxazolidinona y lactoferrina
JP4906247B2 (ja) コンタクトレンズを装用したままで点眼できる点眼薬
RU2012103982A (ru) Офтальмологические композиции с этиленоксид-бутиленоксидными блок-сополимерами
JP2019189607A (ja) 眼科組成物

Legal Events

Date Code Title Description
FC Refusal